Diabetes Clinical Trials in Chicago
View 138 new treatments for Diabetes in Chicago, IL, and nearby areas, such as Naperville. Every day, Power helps hundreds of diabetes patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Naltrexone + Bupropion for Obesity
Currax Clinic, Round Lake Beach + 2 more
This trial studies the effects of a medication combination (naltrexone and bupropion) on heart health. It targets patients to see if this treatment increases the risk of major heart problems. The study also includes advice on diet and exercise. Naltrexone and bupropion have been used in combination for weight loss, but they have been associated with various adverse effects, including neuropsychiatric disorders and cardiovascular risks.Show More
Verified
Recruiting
Phase 4
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team
INV 202 for Diabetic Kidney Disease
Inversago Clinic, Chicago + 2 more
This trial tests a new drug called INV-202 in adults with Diabetic Kidney Disease caused by Type 1 or Type 2 diabetes. The goal is to see if the drug is effective, safe, and well-tolerated, and how it behaves in the body.Show More
Verified
Recruiting
Phase 2
Est. 5 - 8 Weeks
Glenn Crater, MD
Study Director
ILUVIEN® Implant for Diabetic Macular Edema
Alimera Sciences Clinic, Lemont + 3 more
This is a randomized, masked, active-controlled, parallel-group, multi-center study that will assess the efficacy of ILUVIEN as a baseline therapy in the treatment of Center Involving DME (CI-DME). The study will enroll patients who are either treatment naïve or have not received any DME treatments for the preceding 12 months as documented in medical records. Patients who received DME treatment \>12 months before screening, must not have received \>4 intravitreal injections. The study will compare 2 treatment regimens: ILUVIEN intravitreal implant (0.19 mg) followed by supplemental aflibercept as needed per protocol criteria (2 mg/0.05 mL), compared to intravitreal aflibercept loading dose (2 mg administered by intravitreal injection every 4 weeks for 5 consecutive doses) followed by supplemental aflibercept as needed per protocol criteria (2 mg/0.05 mL).Show More
Waitlist
No Placebo Trial
Phase 4
Est. 6 - 12 Weeks
Samer Kaba, MD
Study Chair
Irrisept Irrigation for Diabetic Foot Ulcers
Research Clinic, Lake In The Hills + 5 more
Irrisept™ irrigation containing Chlorhexidine Gluconate (CHG) 0.05% in sterile water, is an irrigation method that may help reduce bacterial load considerably more than traditional saline irrigation.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 5 - 8 Weeks
Patrick McEneaney, DPM
Principal Investigator
Metformin for Prediabetes
Research Clinic, Hines + 2 more
This trial is testing whether metformin can lower the risk of death, heart attacks, and strokes in people with pre-diabetes and heart or blood vessel issues. Metformin is a drug that helps control blood sugar levels and has been used to treat type 2 diabetes mellitus for more than 60 years. The study involves patients who have pre-diabetes and existing heart or blood vessel problems, aiming to see if metformin can provide additional health benefits.Show More
Recruiting
Phase 4
Est. 3 - 6 Weeks
Gregory G. Schwartz, PhD MD
Study Chair
Faricimab for Diabetic Macular Edema
Research Clinic, Oak Forest + 1 more
This study will assess a pragmatic, treat and extend regimen of faricimab against the standard of a fixed dosing regimen.
Recruiting
No Placebo Trial
Phase 4
Est. 5 - 8 Weeks
Dr. Varun Chaudhary, MD, FRCS(C)
Principal Investigator
Continuing vs Holding Metformin for Type 2 Diabetes
Research Clinic, Chicago + 1 more
A randomized study of continuing versus holding metformin during hospitalizations to internal medicine services to determine the effects on glucose control, acidosis, abdominal symptoms, length of stay, and mortality.Show More
Waitlist
No Placebo Trial
Phase 4
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Faricimab for Diabetic Macular Edema
Genentech Clinic, Oak Forest + 2 more
This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treated with faricimab. The study population will consist of participants ≥18 years of age who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander; in addition, a cohort of Asian Indian participants will be enrolled in India.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 3 - 12 Weeks
Clinical Trials
Study Director
Bariatric Surgery vs. Medication for Type 2 Diabetes
Research Clinic, Chicago + 1 more
This study will test the hypothesis that metabolic bariatric surgery will be more effective at providing durable glycemic control and reduce co-morbidities than intensive medical therapy in youth with type 2 diabetes.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 5 - 8 Weeks
Amy S Shah, MD MS
Principal Investigator
Infliximab Optimization for Crohn's Disease
Research Clinic, Chicago + 2 more
This trial tests if using a computer program to decide infliximab doses is better and safer than standard dosing for patients with inflammatory bowel disease. The program helps doctors choose the best dose by looking at individual health details, aiming to keep the medication working well and prevent the disease from getting worse. Infliximab is commonly used to treat inflammatory bowel disease, and dose optimization has been shown to improve treatment outcomes.Show More
Waitlist
No Placebo Trial
Phase 4
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Page 1 of 13
Frequently Asked Questions
Explore related conditions